New hope for deadliest breast cancer complication: drug combo trial launches
NCT ID NCT06462092
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs—sacituzumab govitecan (given through a vein) and pemetrexed (given into the spinal fluid)—for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). This condition is very serious, with survival typically only 3-6 months. The trial aims to find a safe dose and see if the combo can help control the disease. About 34 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Affiliated Huizhou Hospital, Guangzhou Medical University
RECRUITINGHuizhou, Guangdong, 516000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Double-Targeted cell therapy outsmart Cancer's hideouts?
- Radioactive nanoparticles target cancer in the Brain's lining
- Spinal fluid clues could help detect breast cancer spread to the brain
- Proton vs. photon: which radiation works better for leptomeningeal metastases?
- New drug zorifertinib aims to fight lung cancer in the brain
- Could an old drug tame cancer in the spinal fluid? new trial aims to find out